Investigation of differences in the anesthetic action of the intravenous anesthetic remimazolam according to gender.

The influence of gender on emergence from general anesthesia with remimazolam - a cofort study in dental and oral surgery patients. - Examining differences in emergence from remimazolam anesthesia by gender

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000051489

Enrollment

Registered

2023-06-30

Start date

2023-06-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dental or oral surgical disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients undergoing general anesthesia at the Department of Dental Anesthesiology, Okayama University Hospital between the date of approval by the director of the research institution and December 31, 2025 2. Patients who are able to obtain written consent with their own free to participate in research. 3. Patients scheduled for total intravenous anesthesia using remimazolam and remifentanil. 4. Patients who are between 18 and 50 years of age at the time of consent 5. Patients with a body mass index (BMI) of less than 30 6. Patients whose American Society of Anesthesiologists physical status (ASA-PS) is 1 7. Patients scheduled for anesthesia less than 4 hours 8. Patients undergoing dental treatment or minor oral surgery. 9. No need receiving opioid analgesics for postoperative analgesia

Exclusion criteria

Exclusion criteria: 1. Patients with contraindications to remimazolam, remifentanil, or rocuronium 2. Patients who require preanesthetic medication 3. Patients who are deemed inappropriate for participation in the study by the principal investigator or study investigator.

Design outcomes

Primary

Measure	Time frame
Time from discontinuation of remimazolam to tracheal extubation	—

Secondary

Measure	Time frame
1. Patient Characteristics (age, weight, height, BMI, sex, medical history, medicine, clinical examination) 2. Surgical information (procedure, operation time, anesthesia time) 3. Blood concentration of remimazolam and its metabolite CNS7054 at discontinuation of remimazolam and tracheal extubation or administration of flumazenil 4. BIS values at discontinuation of remimazolam and tracheal extubation or administration of flumazenil 5. Remimazolaml amount and average infusion rate of remimazolam 6. Remifentanil amount and average infusion rate of remifentanil 7. BIS values at pre-anesthesia, loss of consciousness, and during anesthesia 8. Time from start of remimazolam to loss of consciousness 9. Number of bolus dose of remimazolam	—

Measure

Time frame

1. Patient Characteristics (age, weight, height, BMI, sex, medical history, medicine, clinical examination) 2. Surgical information (procedure, operation time, anesthesia time) 3. Blood concentration of remimazolam and its metabolite CNS7054 at discontinuation of remimazolam and tracheal extubation or administration of flumazenil 4. BIS values at discontinuation of remimazolam and tracheal extubation or administration of flumazenil 5. Remimazolaml amount and average infusion rate of remimazolam 6. Remifentanil amount and average infusion rate of remifentanil 7. BIS values at pre-anesthesia, loss of consciousness, and during anesthesia 8. Time from start of remimazolam to loss of consciousness 9. Number of bolus dose of remimazolam

—

Countries

Japan

Contacts

Public ContactHitoshi Higuchi

Okayama University Hospital Department of Dental Anesthesiology

higuti@md.okayama-u.ac.jp086-235-6721

Outcome results